Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Description:
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.